(Boursier.com) — Against the general trend, Sartorius Stedim offers a nice rebound this Friday with a title that gains 3% to 377 euros. Heavily shaken since January 1, the title of the supplier of equipment and services to the biopharmaceutical industry is supported by a note from Societe Generale which raised its recommendation on the stock to ‘buy’ while raising its target from 503 at 510 euro. BNP Paribas Exane has also reiterated its opinion ‘outperform’ despite a target reduced from 540 to 510 euros. The group yesterday announced 2021 revenue up 52.6% to 2.89 billion euros and anticipates sales growth of 14% to 18% in 2022. It also expects its underlying EBITDA margin remains at a high level and reaches more than 35%.
Based on the company’s performance in fiscal 2021, management again raised its medium-term profitability forecast. The Group’s underlying EBITDA margin is now expected to be above 35% in 2025 (vs. 33% previously). The margin target already includes spending around 1% of Group revenue on measures to reduce the company’s CO2 emissions intensity. These medium-term objectives still do not include any pandemic-related activities, as management currently considers these estimates to be too uncertain.
©2022 Boursier.com